Fixed treatment with ibrutinib and obinutuzumab for untreated CLL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests a fixed-length treatment plan using ibrutinib plus obinutuzumab for people with newly diagnosed, active CLL/SLL that needs treatment. It may help control the leukemia/lymphoma by combining a targeted drug with an antibody therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and have CLL or SLL that meets standard diagnostic guidelines
- Have not received any past treatment for CLL/SLL (no chemo, targeted drugs, immunotherapy, radiation, or antibody treatment)
- Have “active” disease that doctors agree needs treatment right now
- Your body function and blood counts must be strong enough (enough white cells, platelets, and hemoglobin)
- Kidney, liver, and blood-clotting tests must be within allowed ranges for study safety
- Have swollen lymph nodes visible on CT scan (more than 1.5 cm at the longest point)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial studies an approach for people with newly diagnosed CLL/SLL (chronic lymphocytic leukemia or related disease) who need treatment. It tests whether alternating two types of chemotherapy with ibrutinib (a targeted pill) can control the disease better and safely.
This trial tests a combination of three drugs (zanubrutinib, sonrotoclax, and obinutuzumab) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment before. The goal is to see if this combination works well and is safe.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.